Last reviewed · How we verify

gefitinib and fulvestrant

AstraZeneca · Phase 2 active Small molecule

gefitinib and fulvestrant is a Small molecule drug developed by AstraZeneca. It is currently in Phase 2 development.

At a glance

Generic namegefitinib and fulvestrant
SponsorAstraZeneca
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about gefitinib and fulvestrant

What is gefitinib and fulvestrant?

gefitinib and fulvestrant is a Small molecule drug developed by AstraZeneca.

Who makes gefitinib and fulvestrant?

gefitinib and fulvestrant is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

What development phase is gefitinib and fulvestrant in?

gefitinib and fulvestrant is in Phase 2.

Related